Renal Cell Cancer and Chronic Kidney Disease.

The association between chronic kidney disease (CKD) and renal cell carcinoma (RCC) is bidirectional and multifactorial. Risk factors such as hypertension, diabetes mellitus, obesity, and smoking increase the risk of both CKD and RCC. CKD can lead to RCC via an underlying cystic disease or oxidative stress. RCC can cause CKD because of the tumor itself, surgical reduction of renal mass (either partial or radical nephrectomy), and perioperative acute kidney injury. Medical therapies such as immune checkpoint inhibitors and vascular endothelial growth factor inhibitors can lead to acute kidney injury and resultant CKD. Clinicians need to be aware of the complex, bidirectional interplay between both diseases.

[1]  K. Jhaveri,et al.  Identifying patients with CKD risk at the time of nephrectomy: When to initiate nephrology consult , 2021, Journal of Onco-Nephrology.

[2]  M. Yanagita,et al.  Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review , 2021, Clinical kidney journal.

[3]  Nicole M. Armstrong,et al.  NMDA-receptor agonist reveals LTP-like properties of 10-Hz rTMS in the human motor cortex , 2021, Brain Stimulation.

[4]  H. Anders,et al.  From Kidney Injury to Kidney Cancer. , 2021, Kidney international.

[5]  A. Czarnecka,et al.  Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function , 2021, Cancer Chemotherapy and Pharmacology.

[6]  T. Powles,et al.  Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.

[7]  Z. Harel,et al.  A Systematic Review of Immune Checkpoint Inhibitor–Associated Glomerular Disease , 2020, Kidney international reports.

[8]  M. Carini,et al.  Acute kidney injury promotes development of papillary renal cell adenoma and carcinoma from renal progenitor cells , 2020, Science Translational Medicine.

[9]  Shayan Shirazian,et al.  Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. , 2020, Journal of the American Society of Nephrology : JASN.

[10]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[11]  J. Eastham,et al.  Impact of Acute Kidney Injury and Its Duration on Long-term Renal Function After Partial Nephrectomy. , 2019, European urology.

[12]  Kazuhiko Yoshida,et al.  Efficacy and safety of axitinib for metastatic renal cell carcinoma in patients on hemodialysis for end‐stage renal disease: Case series of eight patients , 2019, International journal of urology : official journal of the Japanese Urological Association.

[13]  G. Sonpavde,et al.  Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials , 2019, Oncology reviews.

[14]  Connie M. Rhee,et al.  Current Management of Patients With Acquired Solitary Kidney , 2019, Kidney international reports.

[15]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  G. Giles,et al.  Tumor size and postoperative kidney function following radical nephrectomy , 2019, Clinical epidemiology.

[17]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[18]  M. Suarez‐Almazor,et al.  Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience , 2019, Journal of Immunotherapy for Cancer.

[19]  E. Plimack,et al.  Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study , 2018, Journal of Immunotherapy for Cancer.

[20]  M. Perazella,et al.  Renal cell carcinoma for the nephrologist. , 2018, Kidney international.

[21]  T. Tsuzuki,et al.  Renal tumors in end‐stage renal disease: A comprehensive review , 2018, International journal of urology : official journal of the Japanese Urological Association.

[22]  T. Choueiri,et al.  Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update , 2018, European journal of cancer.

[23]  M. Okumi,et al.  Impact of preoperative proteinuria on renal functional outcomes after open partial nephrectomy in patients with a solitary kidney , 2017, Investigative and clinical urology.

[24]  M. Kaushik,et al.  A Review of Von Hippel-Lindau Syndrome , 2017, Journal of kidney cancer and VHL.

[25]  E. Tartour,et al.  Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer , 2017, ESMO Open.

[26]  I. Derweesh,et al.  Chronic Kidney Disease Is More Common in Locally Advanced Renal Cell Carcinoma. , 2017, Urology.

[27]  D. Leaf,et al.  Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. , 2016, Kidney international.

[28]  B. Lane,et al.  Proteinuria is a Predictor of Renal Functional Decline in Patients with Kidney Cancer. , 2016, The Journal of urology.

[29]  L. Moore,et al.  Risk of Renal Cell Carcinoma Among Kidney Transplant Recipients in the United States , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  D. Parekh,et al.  Current Paradigm for Ischemia in Kidney Surgery. , 2016, The Journal of urology.

[31]  A. Rowland,et al.  Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data , 2016, British Journal of Cancer.

[32]  R. Pfeiffer,et al.  Variation in Cancer Incidence among Patients with ESRD during Kidney Function and Nonfunction Intervals. , 2016, Journal of the American Society of Nephrology : JASN.

[33]  K. Wagatsuma,et al.  Estimation Using an Enhancement Factor on Non Local Thermodynamic Equilibrium Behavior of High-lying Energy Levels of Neutral Atom in Argon Radio-Frequency Inductively-Coupled Plasma , 2016, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.

[34]  B. Lane,et al.  Impact of Reduced Glomerular Filtration Rate and Proteinuria on Overall Survival of Patients with Renal Cancer. , 2016, The Journal of urology.

[35]  D. K. Choi,et al.  Compensatory Structural and Functional Adaptation after Radical Nephrectomy for Renal Cell Carcinoma According to Preoperative Stage of Chronic Kidney Disease. , 2015, The Journal of urology.

[36]  S. Campbell,et al.  Decline in renal function after partial nephrectomy: etiology and prevention. , 2015, The Journal of urology.

[37]  R. Hebbel,et al.  Sickle cell disease: renal manifestations and mechanisms , 2015, Nature Reviews Nephrology.

[38]  J. Kaouk,et al.  Compensatory hypertrophy after partial and radical nephrectomy in adults. , 2014, The Journal of urology.

[39]  I. Derweesh,et al.  Chronic kidney disease due to surgical removal of nephrons: relative rates of progression and survival. , 2014, The Journal of urology.

[40]  A. Go,et al.  CKD and the risk of incident cancer. , 2014, Journal of the American Society of Nephrology : JASN.

[41]  C. Gachet,et al.  Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey , 2014, Journal of thrombosis and haemostasis : JTH.

[42]  S. Seshan,et al.  Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. , 2014, Human pathology.

[43]  C. Muo,et al.  Increased Risk of End-Stage Renal Disease in Patients with Renal Cell Carcinoma: A 12-Year Nationwide Follow-Up Study , 2014, Medicine.

[44]  A. Weinberg,et al.  Renal insufficiency is associated with an increased risk of papillary renal cell carcinoma histology , 2014, International Urology and Nephrology.

[45]  Adam B. Shrewsberry,et al.  Renal cell carcinoma in patients with end‐stage renal disease has favorable overall prognosis , 2014, Clinical transplantation.

[46]  W. Lowrance,et al.  Association of cancer with moderately impaired renal function at baseline in a large, representative, population‐based cohort followed for up to 30 years , 2013, International journal of cancer.

[47]  J. Soria,et al.  Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[49]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[50]  N. Grishin,et al.  A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma , 2013, Molecular Cancer Research.

[51]  B. Lane,et al.  Surgically induced chronic kidney disease may be associated with a lower risk of progression and mortality than medical chronic kidney disease. , 2013, The Journal of urology.

[52]  S. Masuda,et al.  Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. , 2012, European journal of pharmacology.

[53]  R. Goldschmeding,et al.  Solid renal tumours of collecting duct origin in patients on chronic lithium therapy , 2012, Clinical kidney journal.

[54]  Lara K. Suh,et al.  Tumour diameter and decreased preoperative estimated glomerular filtration rate are independently correlated in patients with renal cell carcinoma , 2012, BJU international.

[55]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[56]  H. Lee,et al.  Post-operative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new-onset chronic kidney disease after radical nephrectomy. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[57]  J. Nakashima,et al.  Impact of tumor size on renal function and prediction of renal insufficiency after radical nephrectomy in patients with renal cell carcinoma. , 2011, The Journal of urology.

[58]  T. Klatte,et al.  Renal cell carcinoma of native kidneys in renal transplant patients , 2011, Current opinion in urology.

[59]  N. Rioux-Leclercq,et al.  Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. , 2011, European urology.

[60]  C. Pan,et al.  Clear cell papillary renal cell carcinoma and clear cell renal cell carcinoma arising in acquired cystic disease of the kidney: an immunohistochemical and genetic study. , 2011, Annals of diagnostic pathology.

[61]  S. Campbell,et al.  Effect of parenchymal volume preservation on kidney function after partial nephrectomy. , 2011, The Journal of urology.

[62]  A. Evans,et al.  Renal cell carcinoma in the native and allograft kidneys of renal transplant recipients. , 2011, The Journal of urology.

[63]  L. Agodoa,et al.  Incidence, predictors and associated outcomes of renal cell carcinoma in long-term dialysis patients. , 2011, Urology.

[64]  Jen‐Hau Chen,et al.  Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[65]  K. Giannakakis,et al.  Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[66]  R. Uzzo,et al.  Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors. , 2011, Urology.

[67]  Robert G Uzzo,et al.  Comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys reveals predominant role of nonmodifiable factors in determining ultimate renal function. , 2011, The Journal of urology.

[68]  J. Larkin,et al.  Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis , 2011, BJU international.

[69]  A. Vathsala,et al.  Native Renal Cysts and Dialysis Duration Are Risk Factors for Renal Cell Carcinoma in Renal Transplant Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[70]  J. McKiernan,et al.  Predicting renal functional outcomes after surgery for renal cortical tumours: a multifactorial analysis , 2010, BJU international.

[71]  E. Rolleman,et al.  Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[72]  M. Salvadori,et al.  Posttransplant proteinuria associated with everolimus. , 2009, Transplantation proceedings.

[73]  C. Ricketts,et al.  Germline SDHB mutations and familial renal cell carcinoma. , 2008, Journal of the National Cancer Institute.

[74]  M. Fischereder.  Cancer in patients on dialysis and after renal transplantation. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[75]  A. Novick,et al.  Correlation between loss of renal function and loss of renal volume after partial nephrectomy for tumor in a solitary kidney. , 2008, The Journal of urology.

[76]  R. Motzer,et al.  Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. , 2007, The Lancet. Oncology.

[77]  A. Schwarz,et al.  Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[78]  Inderbir S Gill,et al.  Factors predicting renal functional outcome after partial nephrectomy. , 2007, The Journal of urology.

[79]  J. Kaldor,et al.  Cancer incidence before and after kidney transplantation. , 2006, JAMA.

[80]  Andrew J Vickers,et al.  Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. , 2006, The Lancet. Oncology.

[81]  D. Bottaro,et al.  Hereditary papillary renal carcinoma type I. , 2004, Current molecular medicine.

[82]  Katsunori Yoshida,et al.  Prediction of postoperative renal function by preoperative serum creatinine level and three-dimensional diagnostic image reconstruction in patients with renal cell carcinoma. , 2004, Urology.

[83]  A. Vaglio,et al.  Prognostic significance of albuminuria in patients with renal cell cancer. , 2003, The Journal of urology.

[84]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[85]  P. Choyke,et al.  Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. , 2003, American journal of human genetics.

[86]  L. Agodoa,et al.  Renal cell carcinoma as a cause of end-stage renal disease in the United States: patient characteristics and survival. , 2003, Kidney international.

[87]  D. Bostwick,et al.  Molecular genetics and histopathologic features of adult distal nephron tumors. , 2002, Urology.

[88]  Maria Merino,et al.  Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. , 2002, Cancer cell.

[89]  R. Colvin,et al.  Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. , 2002, Kidney international.

[90]  S. Birkeland,et al.  Cancer risk in patients on dialysis and after renal transplantation , 2000, The Lancet.

[91]  P. Boyle,et al.  Cancer in patients on dialysis for end-stage renal disease: an international collaborative study , 1999, The Lancet.

[92]  D. Butkus,et al.  Prospective pretransplant ultrasound screening in 206 patients for acquired renal cysts and renal cell carcinoma. , 1998, Transplantation.

[93]  F. Waldman,et al.  The genetics of renal tumors in end-stage renal failure differs from those occurring in the general population. , 1998, Journal of the American Society of Nephrology : JASN.

[94]  Hanlee P. Ji,et al.  Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. , 1997, American journal of human genetics.

[95]  L. Schmidt,et al.  Renal cell carcinoma of end-stage renal disease: a histopathologic and molecular genetic study. , 1996, Journal of the American Society of Nephrology : JASN.

[96]  L. Truong,et al.  Renal neoplasm in acquired cystic kidney disease. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[97]  T. Rand,et al.  Prevalence of acquired cystic kidney disease and tumors in native kidneys of renal transplant recipients: a prospective US study. , 1995, Radiology.

[98]  P. Choyke,et al.  Original Articles: Kidney Cancer , 1995 .

[99]  I. Ishikawa.  Re: Acquired cystic disease of the kidney: a management dilemma. , 1993, The Journal of urology.

[100]  G. Kovacs,et al.  High incidence of papillary renal cell tumours in patients on chronic haemodialysis , 1993, Histopathology.

[101]  A. Novick,et al.  Long-term follow-up after partial removal of a solitary kidney. , 1991, The New England journal of medicine.

[102]  F. Port,et al.  Neoplasms in dialysis patients: a population-based study. , 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[103]  A. Matas,et al.  INCREASED INCIDENCE OF MALIGNANCY DURING CHRONIC RENAL FAILURE , 1975, The Lancet.

[104]  T. Starzl,et al.  A summary of the status of de novo cancer in transplant recipients. , 1972, Transplantation proceedings.

[105]  J. Herrmann,et al.  Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[106]  M. Perazella,et al.  Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? , 2019, Kidney international.

[107]  A. Czarnecka,et al.  Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma. , 2017, Future oncology.

[108]  L. Gesualdo,et al.  Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population , 2014, World Journal of Urology.

[109]  K. Nathanson,et al.  Hereditary kidney cancer syndromes. , 2014, Advances in chronic kidney disease.

[110]  H. Sung,et al.  Small tumour size is associated with new-onset chronic kidney disease after radical nephrectomy in patients with renal cell carcinoma. , 2014, European journal of cancer.

[111]  A. Shalhav,et al.  Chronic kidney disease before and after partial nephrectomy. , 2011, The Journal of urology.

[112]  P. Boyle,et al.  Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. , 2003, Journal of the American Society of Nephrology : JASN.

[113]  P. Godley,et al.  Renal cell carcinoma. , 2002, Current opinion in oncology.

[114]  V. Pateras.  Renal cancer complicating acquired cystic kidney disease. , 1994, Journal of the American Society of Nephrology : JASN.

[115]  J. Brooks,et al.  Adult Urology Oncology: Adrenal/Renal/Upper Tract/Bladder The Urine Albumin-to-Creatinine Ratio and Kidney Function after Nephrectomy , 2022 .